232 related articles for article (PubMed ID: 36172362)
1. Immunoprofiling of monocytes in STAT1 gain-of-function chronic mucocutaneous candidiasis.
Bloomfield M; Zentsova I; Milota T; Sediva A; Parackova Z
Front Immunol; 2022; 13():983977. PubMed ID: 36172362
[TBL] [Abstract][Full Text] [Related]
2. Neutrophils in STAT1 Gain-Of-Function Have a Pro-inflammatory Signature Which Is Not Rescued by JAK Inhibition.
Parackova Z; Vrabcova P; Zentsova I; Sediva A; Bloomfield M
J Clin Immunol; 2023 Oct; 43(7):1640-1659. PubMed ID: 37358695
[TBL] [Abstract][Full Text] [Related]
3. Aberrant tolerogenic functions and proinflammatory skew of dendritic cells in STAT1 gain-of-function patients may contribute to autoimmunity and fungal susceptibility.
Parackova Z; Zentsova I; Vrabcova P; Sediva A; Bloomfield M
Clin Immunol; 2023 Jan; 246():109174. PubMed ID: 36372319
[TBL] [Abstract][Full Text] [Related]
4. Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.
Bloomfield M; Kanderová V; Paračková Z; Vrabcová P; Svatoň M; Froňková E; Fejtková M; Zachová R; Rataj M; Zentsová I; Milota T; Klocperk A; Kalina T; Šedivá A
J Clin Immunol; 2018 Jul; 38(5):589-601. PubMed ID: 29934865
[TBL] [Abstract][Full Text] [Related]
5. Ruxolitinib treatment of a patient with steroid-dependent severe autoimmunity due to STAT1 gain-of-function mutation.
Moriya K; Suzuki T; Uchida N; Nakano T; Katayama S; Irie M; Rikiishi T; Niizuma H; Okada S; Imai K; Sasahara Y; Kure S
Int J Hematol; 2020 Aug; 112(2):258-262. PubMed ID: 32180118
[TBL] [Abstract][Full Text] [Related]
6. Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.
Okada S; Asano T; Moriya K; Boisson-Dupuis S; Kobayashi M; Casanova JL; Puel A
J Clin Immunol; 2020 Nov; 40(8):1065-1081. PubMed ID: 32852681
[TBL] [Abstract][Full Text] [Related]
7. Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory research.
Asano T; Noma K; Mizoguchi Y; Karakawa S; Okada S
Immunol Rev; 2024 Mar; 322(1):81-97. PubMed ID: 38084635
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
[TBL] [Abstract][Full Text] [Related]
9. Case Report: A New Gain-of-Function Mutation of
Martinot M; Korganow AS; Wald M; Second J; Birckel E; Mahé A; Souply L; Mohseni-Zadeh M; Droy L; Tarabeux J; Okada S; Migaud M; Puel A; Guffroy A
Front Immunol; 2021; 12():760019. PubMed ID: 34987506
[TBL] [Abstract][Full Text] [Related]
10. The Extended Clinical Phenotype of 26 Patients with Chronic Mucocutaneous Candidiasis due to Gain-of-Function Mutations in STAT1.
Depner M; Fuchs S; Raabe J; Frede N; Glocker C; Doffinger R; Gkrania-Klotsas E; Kumararatne D; Atkinson TP; Schroeder HW; Niehues T; Dückers G; Stray-Pedersen A; Baumann U; Schmidt R; Franco JL; Orrego J; Ben-Shoshan M; McCusker C; Jacob CM; Carneiro-Sampaio M; Devlin LA; Edgar JD; Henderson P; Russell RK; Skytte AB; Seneviratne SL; Wanders J; Stauss H; Meyts I; Moens L; Jesenak M; Kobbe R; Borte S; Borte M; Wright DA; Hagin D; Torgerson TR; Grimbacher B
J Clin Immunol; 2016 Jan; 36(1):73-84. PubMed ID: 26604104
[TBL] [Abstract][Full Text] [Related]
11. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B; Lambourne J; Porter S; Hodgson T
Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
[TBL] [Abstract][Full Text] [Related]
12. Patients with STAT1 Gain-of-function Mutations Display Increased Apoptosis which is Reversed by the JAK Inhibitor Ruxolitinib.
Dotta L; Todaro F; Baronio M; Giacomelli M; Pinelli M; Giambarda M; Brognoli B; Greco S; Rota F; Cortesi M; Soresina A; Moratto D; Tomasi C; Ferraro RM; Giliani S; Badolato R
J Clin Immunol; 2024 Apr; 44(4):85. PubMed ID: 38578354
[TBL] [Abstract][Full Text] [Related]
13. Case report: Myocarditis in congenital STAT1 gain-of function.
Staels F; Roosens W; Giovannozzi S; Moens L; Bogaert J; Iglesias-Herrero C; Gijsbers R; Bossuyt X; Frans G; Liston A; Humblet-Baron S; Meyts I; Van Aelst L; Schrijvers R
Front Immunol; 2023; 14():1095595. PubMed ID: 37020552
[TBL] [Abstract][Full Text] [Related]
14. [Chronic mucocutaneous candidiasis with STAT1 gain-of-function mutation associated with herpes virus and mycobacterial infections].
Baghad B; Benhsaien I; El Fatoiki FZ; Migaud M; Puel A; Chiheb S; Bousfiha AA; Ailal F
Ann Dermatol Venereol; 2020 Jan; 147(1):41-45. PubMed ID: 31677808
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG; Charbonnier LM; Alroqi F; Plant A; Qiao Q; Wu H; Ma C; Torgerson TR; Rosenzweig SD; Fleisher TA; Notarangelo LD; Hanson IC; Forbes LR; Chatila TA
J Allergy Clin Immunol; 2017 May; 139(5):1629-1640.e2. PubMed ID: 28139313
[TBL] [Abstract][Full Text] [Related]
16. Human STAT1 gain-of-function iPSC line from a patient suffering from chronic mucocutaneous candidiasis.
Haake K; Wüstefeld T; Merkert S; Lüttge D; Göhring G; Auber B; Baumann U; Lachmann N
Stem Cell Res; 2020 Mar; 43():101713. PubMed ID: 32000109
[TBL] [Abstract][Full Text] [Related]
17. Chinese Pedigree of Chronic Mucocutaneous Candidiasis Due to STAT1 Gain-of-Function Mutation: A Case Study and Literature Review.
Wang X; Zhao W; Chen F; Zhou P; Yan Z
Mycopathologia; 2023 Apr; 188(1-2):87-97. PubMed ID: 36335528
[TBL] [Abstract][Full Text] [Related]
18. Interferon signature in patients with STAT1 gain-of-function mutation is epigenetically determined.
Kaleviste E; Saare M; Leahy TR; Bondet V; Duffy D; Mogensen TH; Jørgensen SE; Nurm H; Ip W; Davies EG; Sauer S; Syvänen AC; Milani L; Peterson P; Kisand K
Eur J Immunol; 2019 May; 49(5):790-800. PubMed ID: 30801692
[TBL] [Abstract][Full Text] [Related]
19. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
20. Case Report: Disseminated
Chen K; Tan J; Qian S; Wu S; Chen Q
Front Immunol; 2021; 12():682350. PubMed ID: 34421897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
